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Objective: To develop a core outcome set (COS) applicable for effectiveness trials of all interventions 
for localised prostate cancer.  
Background: Many treatments exist for localised prostate cancer, although it is unclear which offers 
the optimal therapeutic ratio. This is confounded by inconsistencies in the selection, definition, 
measurement and reporting of outcomes in clinical trials. 
Subjects and methods: A list of 79 outcomes was derived from a systematic review of published 
localised prostate cancer effectiveness studies and semi-structured interviews with 15 prostate 
cancer patients. A two-stage consensus process involving 118 patients and 56 international 
healthcare professionals (HCPs) (cancer specialist nurses, urological surgeons and oncologists) was 
undertaken, consisting of a three-round Delphi survey followed by a face-to-face consensus panel 
meeting of 13 HCPs and 8 patients. 
Results: The final COS included 19 outcomes. Twelve apply to all interventions: death from prostate 
cancer, death from any cause, local disease recurrence, distant disease recurrence/metastases, 
disease progression, need for salvage therapy, overall quality of life, stress urinary incontinence, 
urinary function, bowel function, faecal incontinence, sexual function. Seven were intervention-
specific: perioperative deaths (surgery), positive surgical margin (surgery), thromboembolic disease 
(surgery), bothersome or symptomatic urethral or anastomotic stricture (surgery), need for curative 
treatment (active surveillance), treatment failure (ablative therapy), and side effects of hormonal 
therapy (hormone therapy). The UK-centric participants may limit the generalisability to other 
countries, but trialists should reason why the COS would not be applicable. The default position 
should not be that a COS developed in one country will automatically not be applicable elsewhere. 
Conclusion: We have established a COS for trials of effectiveness in localised prostate cancer, 
applicable across all interventions which should be measured in all localised prostate cancer 
effectiveness trials. 
 
1. Introduction  
Treatments for localised prostate cancer can be associated with side effects such as urinary 
incontinence, erectile dysfunction or bowel dysfunction. These may be permanent and cause 
significant impairment of quality of life. (1) The choice between treatments is driven by the 
therapeutic ratio with a balance between cancer control and the likelihood of experiencing adverse 
events, speed of return to routine activities and long-term impact on health-related quality of life. 
(2, 3) 
 
 
It is therefore critical that outcomes important to all stakeholders are measured and reported. 
However, many systematic reviews of effectiveness (4-9) and clinical practice guidelines (10) 
acknowledge the difficulties in synthesising the evidence base due to heterogeneity in outcome 
selection, definitions, measurement and reporting across different trials.  
A potential solution is a “core outcome set” (COS), which is a minimum set of outcomes that should 
be measured and reported in effectiveness trials in a particular condition. (11) Its use can reduce 
heterogeneity in outcome selection, measurement and reporting across trials, and facilitate 
evidence synthesis. (12, 13) 
A ‘standard set of patient-centred’ outcomes was developed by Martin et al (14). However, Martin 
et al’s purpose was to provide quality indicators for institutional registries, “outside of clinical trials” 
(15) with which clinicians or hospitals may measure themselves competitively to “drive competition 
around value”.  As such, their work was not a COS for effectiveness trials. (14) Furthermore, the 
inclusion of only two patients in Martin et al’s consensus process is unlikely to be sufficient and may 
have biased any results toward clinician preference. (16) Lastly, the tools used to measure their 
standard set were not evaluated transparently or robustly with regards to measurement properties 
and feasibility. (13) It is currently unclear which measures should be used in the outcomes measured 
in clinical trials. 
We report here the results of the development and establishment of a COS for intervention 
effectiveness trials for localised prostate cancer. The intention was to identify core outcomes which 
were applicable across all intervention and outcomes which may be intervention-specific. The scope 
of the project led to the appropriate methods (outlined below) which are advocated by the COMET 
initiative, (11, 12) and are explained further in our study protocol. (17) We report our study in line 
with the COS-STAR reporting guidance. (18) 
1.2 Aims and objectives 
The aim was to establish a COS for trials of primary interventions for localised prostate cancer 
(defined as clinical TNM stage ≤T2N0M0) (19) which is applicable across all interventions, including 
adjuvant hormonal therapy.   
Specific objectives were to:  
1. Achieve consensus amongst patients and healthcare professionals on outcomes critically 
important to decision-making; and 
2. Establish a COS for use in future trials assessing interventions for localised prostate cancer. 
2. Materials and Methods 
2.1 Protocol registration and ethical approval 
The methodology used was that recommended by the COMET Initiative – the international expert 
body dedicated to the robust development of COS. (20) The study protocol was published (17) and 
the study approved by the National Research Ethics Service (NRES) – North of Scotland Committee 
(reference 12/NS0042). A project steering committee was established to provide oversight. 
2.2 Achieving consensus amongst patients and healthcare professionals on critically 
important outcomes  
The consensus building process was divided into two phases: (1) Delphi survey involving prostate 
cancer patients in the UK, and healthcare professionals (HCPs) involved in the management of 
localised prostate cancer across the UK, Europe and the USA; and (2) formal consensus group 
meeting involving patients and HCPs.  
 
 
2.2.1 Delphi survey 
Delphi surveys are a well-recognised and increasingly-used consensus method for COS development. 
(21)  A systematic review of the literature was initially performed to ascertain the full range of 
outcomes that had previously been reported in trials of interventions for localised prostate cancer. 
(22) In addition, semi-structured interviews were conducted with a purposive sample of patients to 
identify any further potentially relevant outcomes. (22)  All identified outcomes where entered into 
a bespoke online Delphi tool, written in C# using WebForms and a MySQL backend. The full list of 
outcomes included in the questionnaire (and their definitions) is shown in Appendix 1. Survey 
participants rated each of the items’ importance for decision-making. 
Patients and HCPs were chosen because they are important stakeholders in the management of 
localised prostate cancer. Participants from the UK were primarily targeted due to feasibility and 
resource issues. Patients were eligible if they had been treated or managed for localised prostate 
cancer and were identified through the UK-based UCAN charity’s prospective patient database (23) 
and through prostate cancer support groups registered in the UK and listed on the National 
Federation of Prostate Cancer Support Groups’ website. (24) HCPs were identified through the 
following membership directories and websites: British Association of Urological Surgeons (BAUS), 
British Association of Urological Nurses (BAUN), European Society for Medical Oncology (ESMO), 
American Society of Clinical Oncology (ASCO), European Association of Urology Guidelines Office, 
and the Cochrane Urology group. Purposive sampling was undertaken, covering different 
treatments, age and time since treatment for patients, and type of HCP (urologist, oncologist, or 
cancer nurse specialist) and area of expertise (robotic or laparoscopic radical prostatectomy, ablative 
therapy, external beam radiotherapy, brachytherapy, and active surveillance).  153 patients and 110 
HCPs were invited, with an anticipated completion rate of 50%. Informed consent was presumed if 
participants registered to take part in the online survey. 
 
The questionnaires and participant information sheets were assessed for face validity in a focus 
group with 6 patients and 5 HCPs. Three iterative rounds were planned, and after round one, 
participants were reminded of their own scores and provided with feedback from within their own 
groups and/or from the other groups. Participants had the opportunity to revise their score, or add 
further items into the survey for incorporation in the following round. No items were dropped 
between rounds. Participants were asked to score the importance of each outcome listed on a 9-
point scale adapted from GRADE (25) (i.e. 1-3 = not important; 4-6 = important; 7-9 = critical; 
together with an ‘unable to score’ option). 
 
Descriptive statistics were used to summarise the results of each round, including the percentage of 
participants scoring each of 1-9 for the outcome. The results for each stakeholder group were 
analysed and presented separately in each round. After the final round, items scored as critical (i.e. 
7-9) by ≥70% of patients and HCPs separately AND not important (i.e. 1-3) by <15% of patients and 
HCPs separately were eligible for inclusion in a preliminary core outcome set (i.e. ‘consensus in’ 
outcomes). Conversely, items scored as not important (i.e. 1-3) by ≥70% of patients and HCPs 
separately and critical (7-9) by <15% of patients and HCPs separately were excluded from further 
analysis (i.e. ‘consensus out’ outcomes). All other outcomes were classified as ‘equivocal’. These 
scoring thresholds were based prior COS projects. (26-28) All outcomes were available for discussion 
and voted on at the consensus group meeting.  
 
2.2.2 Consensus group meeting 
A one-day consensus group meeting was held to review the preliminary COS derived from the Delphi 
survey, and to discuss, deliberate and vote in order to establish the final COS. Patients and HCPs 
were purposively sampled from those completing all rounds of the Delphi survey to ensure 
representation of patients receiving the range of treatment types, and urologists, oncologists and 
cancer nurse specialists. Non-voting observers, a patient and public involvement coordinator (PPI), 
and non-clinical members of the project steering group also attended. The meeting was chaired by a 
member of the Steering Group [PRW]. 
Voting was undertaken anonymously using personalised electronic handsets. (29) All items were 
individually presented, reviewed, discussed and voted upon regarding their importance for decision-
making. Participants were asked “Is this outcome important enough to be included in the COS?” and 
asked to score the outcomes on the same 1-9 scale as the Delphi survey.  Items scored as critical (i.e. 
7-9) by ≥70% and not important (i.e. 1-3) by <15% of voting members were eligible for inclusion in 
the final COS. The results for an outcome were conveyed to participants immediately after voting, 
and the final COS was shown to all participants at the end of the meeting.  
3. Results 
An overview of the COS development process and summary of results can be seen in Figure 1.  
3.1 Consensus amongst patients and healthcare professionals on critically important 
outcomes 
3.1.1 Delphi survey  
The systematic review and patient interviews generated 79 discrete outcomes which were 
incorporated into an online questionnaire (Appendix 1). A total of 152 participants completed all 3 
rounds of the survey. Of these, 47 (31%) were HCPs and 105 (69%) were patients. The completion 
rate (i.e. proportion who completed all 3 rounds of the survey out of those invited) was 43% for 
HCPs and 69% for patients.  The overall attrition rate (i.e. drop outs between rounds 1 and 3) was 
13%. We investigated whether attrition may have introduced bias by comparing the mean (SD) 
round 1 scores for those completing round 1 and round 2 (5.9 (1.3)) with those who dropped out 
after round 1 (5.8 (1.5)). We then repeated this for mean (SD) round 2 scores for those completing 
round 2 and 3 (6 (1.2)), compared with those who dropped out after round 2 (5.7 (0.7)). Those 
dropping out between rounds did not appear to hold different views, suggesting that there was no 
attrition bias.   
Tables 1a and 1b summarise the treatment/expertise characteristics of the patients and HCPs who 
completed all 3 rounds of the survey. In addition, the detailed characteristics of HCPs completing all 
3 rounds are included in Appendix 2. Five additional outcomes were proposed by participants in 
round 1 (impact on relationship with partner, bladder pain, urinary tract infection, induction of new 
cancers, and side effects of hormonal therapy), and these were incorporated into subsequent 
rounds. Table 2 summarises the results from Delphi survey round three, showing how each outcome 
was finally scored by patients and HCPs with the results expressed as proportions for each category 
of ‘not important’, ‘important’, and ‘critical’, for the entire study cohort. The outcomes which 
fulfilled the criteria for ‘consensus in’, and ‘equivocal’ outcomes are indicated. No outcomes met the 
criteria for ‘consensus out’.  
3.1.2 Consensus group meeting  
The consensus group meeting was held at the University of Aberdeen, Scotland on the 22nd February 
2016. A total of 21 voting members attended (8 patients, 13 HCPs). The list of participants along with 
their expertise is given in Table 3. For patients, the median [IQR] time since treatment was 3.5 [2.6-
4.3] years. The complete results of the Delphi survey were presented and discussed.  
Following discussion, four outcomes (urinary function, bowel function, sexual function and overall 
quality of life) were grouped back into broader domains. This was done because there was a split 
vote i.e. that everyone voted some aspect of those domains as critical (7-9) but not all voted for the 
same aspect.  Consequently, this was a pragmatic means of taking into account the heterogeneity of 
responses from the Delphi survey and consensus meeting in regard to those discrete outcomes 
Therefore, these multi-dimensional outcomes will need careful consideration of appropriate 
measurement instruments – which is part of the planned future research. The original categories for 
urinary function, bowel function, sexual function and overall quality of life outcomes before re-
categorisation can be viewed in Appendix 1.   
The results of the voting for each outcome are summarised in Appendix 3. The final core outcome 
set is summarised in Table 4, along with the interventions each core outcome is relevant to. The final 
COS contains 19 outcomes, with 12 universal outcomes (i.e. relevant across all interventions) and 7 
intervention-specific ones (4 for surgery, and one each for active surveillance, 
cryotherapy/HIFU/ablative therapy, and hormonal therapy).  
Discussion 
Our study adopted robust methods to generate a core outcome set relevant to trials of interventions 
for localised prostate cancer.  From the consensus process, 19 core outcomes were identified: 12 
universal and 7 intervention-specific, covering all domains of cancer control and survival, urinary 
function, bowel function, sexual function, quality of life, and adverse events.  
There have been two recent reports on developing standardised outcomes in the field of localised 
prostate cancer. Martin et al. (14) defined a set of health outcomes for localised prostate cancer 
management, to be measured in routine clinical practice with the purpose of determining the value 
of health care interventions;  (14) and van den Bos et al. (30) reported on a consensus statement 
regarding the design of future trials of focal ablative therapy for a sub-set of patients with localised 
prostate cancer.  Additional insights provided by our study are that it is the first localised prostate 
cancer study that takes into account the opinions of patients on a large scale and uses robust and 
transparent methods planned a priori.  
Whilst it is encouraging that there is broad overlap between Martin et al’s outcomes recommended 
for clinical practice and our COS for effectiveness trials, it is important to reiterate the differences in 
the aims of the two studies, i.e. we aimed to develop a COS for effectiveness trails, Martin et al’s 
standard-set was not designed for trials but for routine clinical practice. It is important also to re-
state the methodological differences. In particular the involvement of only two patients in Martin et 
al’s consensus process is unlikely to sufficiently capture patient opinion. (15, 16, 31) Ultimately, it is 
desirable for routine clinical data and data from trials to be commensurable, particularly in situations 
where routine data (such as rare events) might be more reliably captured in long-term institutional 
databases as opposed to the trial setting.  
Van den Bos et al’s recommended primary outcome measure (negative biopsy at 12 months after 
treatment) (30) is encompassed within our outcome of treatment failure for ablative therapy in our 
COS. There are important differences between this study and our COS study. First, our COS study 
had a broader scope encompassing all current treatments for localised prostate cancer rather than a 
single type of intervention for a subset of patients with certain disease characteristics. Also, their 
expert group had no patient representation; the Delphi process does not give adequate information 
to assess how information was fed back to participants between rounds, and may have influenced 
subsequent rounds; and it is unclear how consensus was reached in the final meeting. (32) 
This study is the most rigorous and largest of its kind, involving a large sample of patients from the 
UK, and HCPs from the UK, Europe and USA, producing a COS specifically developed for localised 
prostate cancer intervention trials using rigorous, protocol-driven, transparent and reproducible 
methods. (17) A comprehensive and robust systematic review to explore, define and characterise 
the nature of heterogeneity of outcome selection, definition and measurement was performed prior 
to a consensus-based process involving a Delphi survey and a consensus group meeting. The study 
involved a large, purposively sampled group of participants which included men with localised 
prostate cancer, and a diverse group of healthcare professionals from the UK, Europe and the USA.  
The Delphi survey included three iterative rounds, whereby feedback on others’ opinions was 
provided to allow participants to reflect, and to revise or maintain their responses as required, in 
addition to proposing any additional outcomes.  
A limitation of the COS is that most of the participants were from the UK. However, we think that 
people in other countries should look at this well-developed COS and ask the question ‘Is there a 
reason why these results would not be similar to those that could be obtained in our population?’ If 
the answer is yes, then clearly more work is needed, but the default position should not be that a 
COS developed in one country will automatically not be applicable elsewhere. Additionally, more 
surgeons completed the survey and participated in the consensus meeting than oncologists. 
However, the HCP group also consisted of specialist nurses who provided crucially important 
perspectives regarding treatment with radiotherapy. 
We assumed that most potentially important outcomes were likely to be reported in studies 
representing the highest levels of evidence only, based on the hierarchy of evidence, (33) on the 
basis that such studies are more likely to guide or change practice, and more likely to measure 
outcomes using validated tools. Although this may be considered a strength, it can also be regarded 
as a limitation because some potentially important outcomes may have been missed from our 
review. However, this risk is minimised by supplementing the long list of potentially important 
outcomes with additional outcomes identified from the semi-structured patient interviews, and 
from the Delphi survey where additional outcomes could be added.   
The problems and issues arising from inconsistency and heterogeneity of outcome selection, 
definition, measurement and reporting in primary and secondary studies of localised prostate cancer 
are well documented. (4, 5, 7, 34, 35) Prospective trials of interventions for localised prostate 
cancer, should consider adopting the COS. Using our COS, future trialists have an opportunity to 
omit other outcomes which are not ‘core’, thereby reducing the burden on trialists, patients and 
funders. Some steps have been directed toward the implementation of the COS inasmuch as the COS 
is listed in the COMET database and COMET is targeting trial funders (e.g. NIHR guidance) and 
trialists (e.g. SPIRIT guidelines) to use COS, where they exist for planned trials.  
Additional outcomes beyond the COS proposed (e.g. economic outcomes, related to use of health 
services, or specific surgical outcomes such as blood loss or anastomotic leak) might need to be 
measured to address questions beyond relative effectiveness, as these outcomes may be 
determinants of the cost and effectiveness components of a cost-effectiveness analysis.(36) There is 
also a valid argument for adopting the COS in clinical practice, since it reflects outcomes of greatest 
importance to patients and HCPs in making healthcare decisions. There is evidence that COS for 
trials align very closely with those required for informed consent (37).  
Future work should focus on how the COS should be defined and measured in practice, 
incorporating elements such as standardising outcome definitions and thresholds, identifying the 
most appropriate measurement instruments, and time points for outcome assessment. We plan to 
address this in the next phase of our project, based on a strategy of appraising existing outcome 
measurement tools using objective criteria, such as those outlined in the OMERACT filter (36) or 
recommended by COSMIN. (13) 
In conclusion, our study reports on the robust development of a comprehensive core outcome set 
for use in trials assessing interventions for localised prostate cancer. The final core outcome set 
includes 19 core outcomes, with 12 universal and 7 intervention-specific.  The routine adoption of 
this COS in future trials of interventions for localised prostate cancer should ensure that outcomes of 
importance to patients and healthcare professionals will be collected and thus facilitate comparisons 
across different studies to allow informed treatment choices for patients, health care professionals 
and service providers.  
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 Table 1a: Summary of characteristics of patients who completed all three rounds of the Delphi 
survey 
 
Patients (N = 105) 
Age N (%) Primary treatment N (%) Time since 
treatment N (%) 
Country of origin N (%)
≤60 
yea
rs 
>60 
yea
rs 
Surge
ry 
EBR
T 
Brachyther
apy 
AS Ablati
ve 
thera
py 
≤1 
ye
ar 
2-5 
yea
rs 
>5 
yea
rs 
Scotla
nd 
Engla
nd 
Wal
es  
19  
(18) 
86 
(82) 
50 
(48) 
26 
(25) 
7 (7) 17
(1
6) 
5 (5) 17
(16
) 
53
(51) 
35
(33) 
20 (19) 72 
(69) 
13
(12) 
 
 
Table 1b: Summary of characteristics of HCPs who completed all three rounds of the Delphi survey 
 
HCPs (N = 47)
Expertise N (%) Country of origin N (%) 
CNS Urological 
surgeon 
Oncologist Scotland England Wales Other European 
countries 
USA
8 
(17) 
31 (66) 8 (17) 25 (53) 12 (26) 1 (2) 7 (15) 2
(4) 
 
Abbreviations: HCPs (health care professionals) CNS (cancer nurse specialist), EBRT (electron beam 
radiotherapy), AS (active surveillance) 
  
 Table 2: Summary of results after three rounds of Delphi survey 
 
Outcomes  
Patients N = 105 HCPs N =  47 Consensus 
from Delphi 
survey  
Not 
important Important Critical 
Not 
important Important Critical 
A.CANCER SPECIFIC AND SURVIVAL OUTCOMES 
1. Death from any cause 2% 6% 92% 0% 2% 98% In 
2. Death from prostate cancer 1% 4% 95% 0% 2% 98% In 
3. Death from causes other than prostate cancer* 2% 9% 89% 0% 6% 94% In 
4. Local disease recurrence 1% 5% 94% 0% 4% 96% In 
5. Distant disease recurrence/metastases 1% 3% 96% 0% 0% 100% In 
6. Disease progression (disease getting worse) 2% 5% 93% 0% 4% 96% In 
7. Need for further treatment to augment primary treatment 2% 10% 88% 0% 19% 81% In 
8. Need for salvage therapy 3% 6% 91% 0% 13% 87% In 
Applicable to active surveillance  
9. Disease reclassification 5% 6% 89% 0% 23% 77% In 
10. Need for curative treatment 5% 9% 86% 0% 4% 96% In 
Applicable to ablative procedures (cryotherapy, HIFU) 
11. Treatment failure 4% 4% 93% 0% 11% 89% In 
12. Retreatment 4% 8% 88% 0% 19% 81% In 
Applicable to surgery 
13. Positive surgical margin 3% 5% 92% 4% 49% 47% Equivocal 
B. BOWEL FUNCTION 
14. Diarrhoea 7% 82% 11% 2% 87% 11% Equivocal 
15. Faecal incontinence 4% 19% 77% 2% 9% 89% In 
16. Faecal urgency 4% 57% 39% 2% 63% 35% Equivocal 
17. Rectal bleeding 6% 38% 56% 4% 57% 39% Equivocal 
18. Rectal itch 15% 79% 6% 15% 80% 4% Equivocal 
19. Constipation 10% 80% 9% 11% 85% 4% Equivocal 
20. Bowel frequency 13% 83% 4% 7% 85% 9% Equivocal 
21. Painful bowel movements 9% 64% 27% 2% 83% 15% Equivocal 
C. URINARY FUNCTION 
22. Urge incontinence 6% 44% 50% 0% 43% 57% Equivocal 
23. Stress incontinence 7% 60% 33% 0% 49% 51% Equivocal 
24. Weak urine stream 10% 79% 11% 7% 87% 7% Equivocal 
25. Nocturia 26% 60% 14% 7% 87% 7% Equivocal 
26. Haematuria 11% 37% 52% 9% 83% 9% Equivocal 
27. Dysuria 9% 53% 38% 2% 91% 7% Equivocal 
28. Frequency 17% 68% 14% 11% 83% 7% Equivocal 
29. Urgency 11% 67% 22% 2% 89% 9% Equivocal 
30. Need for a temporary urethral catheter 27% 34% 39% 23% 72% 4% Equivocal 
31. Catheter-related problems 10% 40% 49% 13% 79% 9% Equivocal 
D. SEXUAL FUNCTION 
32. Erectile dysfunction 10% 52% 38% 0% 68% 32% Equivocal 
33. Reduced or loss of libido 8% 66% 26% 0% 94% 6% Equivocal 
34. Frequency of intercourse 14% 72% 14% 9% 89% 2% Equivocal 
35. Ejaculatory function 18% 60% 22% 21% 79% 0% Equivocal 
36. Orgasmic function 10% 63% 27% 2% 98% 0% Equivocal 
37. Sexual function 10% 61% 29% 0% 83% 17% Equivocal 
E. OPERATION SPECIFIC AND HOSPITAL-STAY OUTCOMES 
Applicable to all treatments apart from Active surveillance 
38. Duration of the procedure 39% 57% 4% 49% 51% 0% Equivocal 
 39. Pain 10% 82% 8% 0% 100% 0% Equivocal 
40. Use of pain relief medications after procedure 8% 82% 10% 9% 91% 0% Equivocal 
41. Catheter duration 13% 71% 16% 17% 83% 0% Equivocal 
42. Duration of hospital stay 34% 61% 5% 13% 87% 0% Equivocal 
43. Time to full recovery 14% 71% 15% 0% 52% 48% Equivocal 
44. Time to partial recovery 17% 76% 7% 4% 93% 2% Equivocal 
Applicable to radical prostatectomy only 
45. Blood loss 18% 56% 26% 2% 82% 16% Equivocal 
F. QUALITY OF LIFE AND EMOTIONAL WELL-BEING 
46. Anxiety 14% 78% 9% 2% 89% 9% Equivocal 
47. Depression 12% 69% 19% 2% 89% 9% Equivocal 
48. Lack of confidence 16% 73% 11% 2% 89% 9% Equivocal 
49. Feeling less masculine 27% 61% 12% 2% 91% 6% Equivocal 
50. Feeling tired or fatigued 10% 73% 17% 0% 94% 6% Equivocal 
51. Overall Quality of LIfe 11% 52% 37% 0% 40% 60% Equivocal 
52. Quality of life relating to urinary function 8% 56% 37% 0% 49% 51% Equivocal 
53. Quality of life relating to sexual function 8% 64% 28% 0% 77% 23% Equivocal 
54. Quality of life relating to bowel function 6% 48% 45% 0% 49% 51% Equivocal 
55. Quality of life impact on immediate family 6% 56% 38% 0% 79% 21% Equivocal 
G. ADVERSE EVENTS DURING AND AFTER HORMONE THERAPY  
56. Hot flushes 26% 72% 2% 4% 91% 4% Equivocal 
57. Swelling of the breast tissue (gynaecomastia) 17% 70% 13% 4% 87% 9% Equivocal 
58. Loss of libido 16% 70% 14% 2% 98% 0% Equivocal 
59. Erectile dysfunction 17% 53% 29% 2% 85% 13% Equivocal 
60. Body fat gain 7% 76% 17% 4% 91% 4% Equivocal 
61. Fatigue 3% 77% 21% 2% 81% 17% Equivocal 
H. ADVERSE EVENTS DURING AND AFTER RADIATION THERAPY 
62. Anal discomfort 8% 82% 10% 0% 96% 4% Equivocal 
63. Urethral stricture 8% 21% 71% 0% 47% 53% Equivocal 
64. Radiation proctitis 9% 52% 39% 0% 53% 47% Equivocal 
65. Acute urinary retention 12% 8% 80% 0% 45% 55% Equivocal 
66. Fatigue 7% 84% 9% 0% 81% 19% Equivocal 
67. Haematuria 15% 60% 25% 4% 77% 19% Equivocal 
I. ADVERSE EVENTS DURING AND AFTER SURGERY  
68. Acute or sub-acute bowel obstruction 10% 8% 82% 0% 29% 71% In 
69. Acute urinary retention 6% 14% 80% 0% 42% 58% Equivocal 
70. Anastomotic leak 8% 18% 74% 0% 64% 36% Equivocal 
71. Blood transfusion 11% 42% 47% 2% 64% 33% Equivocal 
72. Wound problems 8% 38% 55% 2% 89% 9% Equivocal 
73. Bowel injury 6% 13% 81% 0% 11% 89% In 
74. Nerve damage or neuropraxia 8% 20% 72% 0% 53% 47% Equivocal 
75. Perioperative deaths 7% 1% 91% 0%   100% In 
76. Prolonged indwelling catheter 6% 31% 63% 7% 80% 13% Equivocal 
77. Thromboembolic disease 8% 3% 89% 0% 11% 89% In 
78. Rectourethral fistula 8% 5% 88% 0% 4% 96% In 
79. Urethral or anastomotic stricture 6% 12% 83% 0% 24% 76% In 
Additional outcomes suggested by participants in Round 1 
80. Impact on relationship with partner 10% 45% 46% 0% 57% 43% Equivocal 
81. Bladder pain  19% 45% 36% 2% 89% 9% Equivocal 
82. Urinary tract infection  19% 46% 36% 6% 89% 4% Equivocal 
83. Induction of new cancers+ 9% 5% 86% 2% 53% 45% Equivocal 
84. Side effects of hormonal therapy  6% 31% 63% 0% 46% 54% Equivocal 
 
Key: Green cells indicate outcomes meeting consensus ‘in’. Red cells indicate ≥70% critical 
*’Death from causes other than prostate cancer’ was originally voted ‘in’, but after discussion it was felt to be structurally related to ‘death from any cause’ and ‘death from prostate cancer’ and therefore voted out.  
 
+‘Induction of new cancers’ was originally voted ‘in’ but after discussion it was felt to be too rare and late occurring an outcome to be feasibly collected in a trial setting and therefore voted out.  
 
Table 3: Expertise and experience of consensus meeting participants 
 
Name Role Expertise/Experience Date of 
treatment 
start 
City, country 
Gary 
Akehurst  
Patient Received treatment for 
localised prostate cancer 
November 
2011 
England (UK) 
Robert 
Almquist 
Patient Received treatment for 
localised prostate cancer 
November 
2013 
England (UK)
Karl Beck Patient Received treatment for 
localised prostate cancer 
January 
2008 
Scotland 
(UK) 
David Budd Patient Received treatment for 
localised prostate cancer 
June 2013 Scotland 
(UK) 
Alexander 
Ewen 
Patient Received treatment for 
localised prostate cancer 
November 
2013 
Scotland 
(UK) 
David Hurst Patient Received treatment for 
localised prostate cancer 
September 
2011 
England (UK) 
Andrew 
Mackie 
Patient Received treatment for 
localised prostate cancer 
June 2012 Scotland 
(UK) 
Hans 
Schreuder 
Patient Received treatment for 
localised prostate cancer 
October 
2012 
England (UK)
Hashim 
Ahmed 
HCP (Surgeon) HIFU NA London, 
England (UK) 
James 
N'Dow 
HCP (Surgeon)/ 
European Association 
of Urology Guidelines 
Office 
 
Surgery and active 
surveillance/ Chair of EAU 
Guidelines Office 
NA Aberdeen, 
Scotland 
(UK) 
Judith Grant HCP (Clinical 
Oncologist) 
EBRT and active surveillance NA Aberdeen, 
Scotland 
(UK) 
Justine 
Royle 
HCP (Surgeon) Robotic/laparoscopic radical 
prostatectomy 
NA Aberdeen, 
Scotland 
(UK) 
Kevin 
Wardlaw 
HCP (CNS) Prostate cancer management NA Aberdeen, 
Scotland 
(UK) 
Nicolas 
Mottet  
HCP 
(Surgeon)/European 
Association of Urology 
Prostate cancer 
guideline panel 
Laparoscopic radical 
prostatectomy/Chair of EAU 
Prostate cancer guideline 
panel 
NA St. Etienne, 
France 
Philip 
Cornford 
HCP 
(Surgeon)/European 
Association of Urology 
Prostate cancer 
guideline panel 
Robotic radical 
prostatectomy/Co-chair of 
EAU Prostate cancer guideline 
panel 
NA Liverpool, 
England (UK) 
Philip Dahm HCP 
(Surgeon)/Cochrane 
Urology editorial 
group 
Open radical 
prostatectomy/Coordinating  
Editor of Cochrane Urology 
NA Minneapolis, 
USA 
Rakesh Heer HCP (Surgeon) Robotic radical prostatectomy NA Newcastle, 
England (UK) 
Rob Jones HCP (Medical 
Oncologist)/Cancer 
Research UK Clinical 
Trials Unit 
Active surveillance, Director of 
CRUK CTU, Beatson Institute 
NA Glasgow, 
Scotland 
(UK) 
Sam 
McClinton 
HCP (Surgeon) Surgery and active 
surveillance 
NA Aberdeen, 
Scotland 
(UK) 
Thomas Lam HCP (Surgeon) Robotic/laparoscopic radical 
prostatectomy 
 
NA Aberdeen, 
Scotland 
(UK) 
William 
Cross 
HCP (Surgeon) Robotic radical prostatectomy NA Leeds, 
England (UK) 
Marion 
Campbell 
Methodologist (Non-
voting)/Health 
Services Research Unit 
Evidence synthesis and 
trials/Chair of Health Services 
Research Unit, Aberdeen 
NA Aberdeen, 
Scotland 
(UK) 
Paula 
Williamson 
Chair  
Methodologist (Non-
Evidence synthesis, trials and 
COS/Chair of COMET Initiative 
Management Group 
NA Liverpool, 
England (UK) 
 Abbreviations: HIFU (high intensity focussed ultrasound), EBRT (electron beam radiotherapy), COS 
(core outcome set), HCP (healthcare professional), UCAN (urological cancer charity), PCASO 
(prostate cancer support organisation), LPC (localised prostate cancer), PPI (patient and public 
involvement) 
  
voting)/COMET 
Steven 
MacLennan 
Methodologist (Non-
voting)  
Evidence Synthesis and 
qualitative research 
NA Aberdeen, 
Scotland 
(UK) 
Linda 
Pennet  
PPI/CNS (Non-voting) Prostate cancer management NA Aberdeen, 
Scotland 
(UK) 
Grigoris 
Athanasiadis 
Observer  Robotic radical prostatectomy NA Aberdeen, 
Scotland 
(UK) 
Rebecca Fish  Observer  Colorectal surgeon and PhD 
student developing COS in 
anal cancer 
NA Bristol, 
England (UK) 
Table 4: Final Core Outcome Set for trials of interventions for localised prostate cancer 
 
Domain  Outcome 
Universal (i.e. applicable to all interventions) 
Cancer/survival Death from prostate cancer 
Cancer/survival Death from any cause 
Cancer/survival Local disease recurrence  
Cancer/survival Distant disease recurrence/metastases  
Cancer/survival Disease progression  
Cancer/survival Need for salvage therapy  
Bowel function Faecal incontinence  
Bowel function Bowel function (including diarrhoea, faecal urgency, rectal bleeding, rectal itch, 
constipation, bowel frequency, and painful bowel movements) 
Urinary 
function 
Stress incontinence  
Urinary 
function 
Urinary function (including urge incontinence, weak urine stream, nocturia, 
haematuria, dysuria, frequency, urgency, need for temporary catheter, and 
catheter related problems) 
Sexual function Sexual function (including erectile dysfunction, reduced or loss of libido, frequency 
of intercourse, ejaculatory function, orgasmic function, and sexual function,) 
Quality of life Overall quality of life (including anxiety, depression, lack of confidence, feeling less 
masculine, feeling tired or fatigued, overall quality of life, quality of life relating to 
urinary function, quality of life relating to sexual function, quality of life relating to 
bowel function and quality of life impact on immediate family) 
Surgery (i.e. radical prostatectomy) 
Cancer/Survival Positive surgical margin 
Adverse events  Perioperative deaths 
Adverse events Thromboembolic disease 
Adverse events Bothersome or symptomatic urethral or anastomotic stricture 
Ablative therapy
 Cancer/survival Treatment failure 
Active surveillance 
Cancer/survival Need for curative treatment  
Hormone Therapy 
Adverse events Side effects of hormonal therapy 
 
  




  
Appendix 2: Detailed Characteristics of HCPs completing all 3 Delphi survey rounds  
 
Name City, country of residence  Expertise  
Alan Mcneill Edinburgh, Scotland (UK) Surgery (lap) 
Alasdair Innes Edinburgh, Scotland (UK) Urology CNS 
Alessandro Volpe Novara, Italy Surgery (robotic) 
Axel Bex Amsterdam, The Netherlands Surgery (robotic) 
Axel Merseburger Hannover, Germany Surgery
Balazs Binnyei Aberdeen, Scotland (UK) Oncology (medical) 
Borje Ljungberg Umea, Sweden Surgery
Brian Corr Inverness, Scotland (UK) Urology CNS 
Danny Lynch Aberdeen, Scotland (UK) Oncology CNS 
David Douglas Inverness, Scotland (UK) Surgery (lap/robotic) 
Debbie Munro Aberdeen, Scotland (UK) Urology CNS 
Duncan McLaren Newcastle, England (UK) Oncology (clinical) 
Eric Borg Aberdeen, Scotland (UK) Urology CNS 
Graham Macdonald Aberdeen, Scotland (UK) Oncology (clinical) 
Grant Stewart Edinburgh, Scotland (UK) Surgery (lap) 
Hashim Ahmed London, England (UK) Surgery (HIFU) 
Henk Van der Poel Amsterdam, The Netherlands Surgery (robotic) 
Hugh Mostafid Basingstoke, England (UK) Surgery (lap) 
Ian Pearce Manchester, England (UK) Surgery (lap) 
James N’Dow Aberdeen, Scotland (UK) Surgery
Jim Catto Sheffield, England (UK) Surgery (robotic) 
Judith Grant Aberdeen, Scotland (UK) Oncology (clinical) 
Justine Royle Aberdeen, Scotland (UK) Surgery (lap/robotic) 
Kevin Wardlaw Aberdeen, Scotland (UK) Urology CNS 
Lesley Simpson Aberdeen, Scotland (UK) Urology CNS 
Linda Pennet Aberdeen, Scotland (UK) Urology CNS 
Malcolm Mason  Cardiff, Wales (UK) Oncology (clinical) 
Nicholas Cohen Aberdeen, Scotland (UK) Surgery 
Nicolas Mottet St. Etienne, France Surgery (lap) 
Pam Barker Aberdeen, Scotland (UK) Surgery 
Paul Abel  London, England (UK) Surgery 
Paul Halliday Dundee, Scotland (UK) Surgery 
Peter Cooke Wolverhampton, England (UK) Surgery 
Philip Cornford Liverpool, England (UK) Surgery (robotic) 
Philipp Dahm Minneapolis, USA Surgery 
Robert Jones Glasgow, Scotland (UK) Oncology (medical) 
Robert Mills Norwich, England (UK) Surgery 
Roger Kocklebergh Leicester, England (UK) Surgery  
Sam McClinton Aberdeen, Scotland (UK) Surgery 
Satchi Swami Aberdeen, Scotland (UK) Surgery  
Steve Leung Dunfermline, Scotland (UK) Surgery 
Steven Canfield  Houston, USA Surgery (robotic) 
Thomas Lam  Aberdeen, Scotland (UK) Surgery (lap/robotic) 
Thomas Wiegel Ulm, Germany  Oncology (clinical) 
William Cross Leeds, England (UK) Surgery (robotic) 
 
  
 Appendix 3: Results of voting for all outcomes voted on during consensus group meeting  
 
Outcome (applicable interventions) Not important   Important  Critical  
A.CANCER SPECIFIC AND SURVIVAL OUTCOMES 
1. Death from any cause (universal)  5% 0% 95%
2. Death from prostate cancer (universal) 0% 5% 95%
3. Death from causes other than prostate cancer (universal) ++ 5% 0% 95%
4. Local disease recurrence (universal) 0% 19% 81%
5. Distant disease recurrence/metastases (universal) 0% 5% 95%
6. Disease progression (universal) 0% 5% 95%
7. Need for further treatment to augment primary treatment 
(universal) 14% 57% 29%
8. Need for salvage therapy (universal) 0% 10% 91%
9. Disease reclassification (Active surveillance)  0% 33% 67%
10. Need for curative treatment (Active surveillance) 0% 14% 86%
11. Treatment failure (Ablative)  0% 5% 95%
12. Retreatment (Ablative)  10% 29% 62%
13. Positive surgical margin (Surgery)  0% 24% 76%
B. BOWEL FUNCTION 
14. Bowel function (universal)* 0% 20% 80%
15. Faecal incontinence (universal) 0% 14% 86%
C. URINARY FUNCTION 
23. Stress incontinence (universal) 14% 14% 71%
24. Urinary Function (universal)* 0% 5% 95%
26. Haematuria (universal) 15% 70% 15%
30. Need for temporary catheter (universal) 40% 60% 0%
31. Catheter-related problems (urinary function)  30% 60% 10%
D. SEXUAL FUNCTION 
37. Sexual Function (universal)* 0% 10% 85%
E. OPERATION SPECIFIC AND HOSPITAL-STAY OUTCOMES 
Applicable to all treatments apart from Active surveillance 
43. Time to full recovery (universal) 14% 67% 19%
F. QUALITY OF LIFE AND EMOTIONAL WELL-BEING 
51. Overall Quality of Life (universal) 5% 10% 86%
52. Quality of life relating to urinary function (universal) 100% 0% 0%
54. Quality of life relating to bowel function (universal) 95% 5% 0%
H. ADVERSE EVENTS DURING AND AFTER RADIATION THERAPY 
63. Bothersome or symptomatic Urethral stricture 0% 24% 76%
 65. Acute urinary retention (all interventions) 10% 48% 43%
66. Fatigue (all interventions) (REWORDED) 0% 35% 65%
68. Acute or sub-acute bowel obstruction (AE surgery)  0% 38% 62%
69. Acute urinary retentionall treatments 100% 0% 0%
I. ADVERSE EVENTS DURING AND AFTER SURGERY 
70. Anastomotic leak 5% 76% 19%
72. Wound problems 29% 62% 10%
74. Nerve damage or neuropraxia  38% 24% 0%
75. Perioperative deaths  5% 5% 91%
77. Thromboembolic disease  0% 29% 71%
79. Bothersome or symptomatic urethral or anastomotic stricture  0% 33% 67%
Additional outcomes suggested by participants in Round 1 of Delphi 
80. Impact on relationship with partner  0% 80% 20%
83. Induction of new cancers §    10% 24% 76%
84. Side effects of hormonal therapy  0% 5% 95%
85. ‘Bowel injury' and 'rectourethral fistula' considered together* 5% 47% 47%
 
Key: Green cells indicate outcomes meeting consensus ‘in’. Red cells indicate ≥70% critical 
++ Although initially voted ‘in’, ‘death from causes other than prostate cancer’ was subsequently 
discussed and voted out because it is structurally related to ‘death from any cause’ and ‘death from 
prostate cancer’.  
§ Although initially voted ‘in’, ‘Induction of new cancers’ was subsequently discussed and voted out 
because it was considered to be very rare and late occurring and therefore unlikely to be feasible to 
collect in effectiveness trials. 
*Outcomes re-categorised during consensus meeting 
‘Bowel function’ includes: diarrhoea, faecal urgency, rectal bleeding, rectal itch, constipation, bowel 
frequency, and painful bowel movements 
‘Urinary function’ includes: urge incontinence, weak urine stream, nocturia, haematuria, dysuria, 
frequency, urgency, need for temporary catheter, and catheter related problems 
‘Sexual function’ includes: erectile dysfunction, reduced or loss of libido, frequency of intercourse, 
ejaculatory function, orgasmic function, and sexual function 
‘Overall quality of life’ includes: anxiety, depression, lack of confidence, feeling less masculine, 
feeling tired or fatigued, overall quality of life, quality of life relating to urinary function, quality of 
life relating to sexual function, quality of life relating to bowel function and quality of life impact on 
immediate family 
 
